LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 801–900 of 1,000
Cidlinsky, N. A., Dogliotti, G., Pukrop, T., Jung, R., Weber, F., & Krahn, M. P. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0290-8 · Cited by 6
Zhong, J., Zheng, Q., Gao, E., Dong, Z., Zhao, J., An, T., Wu, M., Zhuo, M., Wang, Y., Li, J., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12581 · Cited by 6
Self-citationTSC2 genetic variant and prognosis in non‐small cell lung cancer after curative surgery
Lee, Y. H., Do, S. K., Lee, S. Y., Kang, H., Choi, J. E., Hong, M. J., Lee, J. H., Lee, E. B., Jeong, J. Y., Shin, K. M., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12951 · Cited by 6
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 7
Rahman, M. A., Ravichandran, R., Sankpal, N. V., Bansal, S., Sureshbabu, A., Fleming, T. P., Perincheri, S., Bharat, A., Smith, M. A., Bremner, R. M., et al. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104690 · Cited by 6
Wang, Z., Piha-Paul, S. A., Jankú, F., Subbiah, V., Shi, N., Gong, J., Wathoo, C., Shaw, K. R. M., Hess, K. R., Broaddus, R. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16840 · Cited by 6
“Because concurrent KRAS and TP53 mutations manifest potentially synergistic biologic effects, cancers carrying both KRAS and TP53 mutations (KRAS+/TP53+) might represent a unique cancer subtype with distinct and aggressive biologic behaviors [16].”
BackgroundLkb1 deletion in murine B lymphocytes promotes cell death and cancer
Souroullas, G. P., Fedoriw, Y. D., Staudt, L. M., & Sharpless, N. E. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.005 · Cited by 6
“In solid tumors, there is strong oncogenic cooperation between Lkb1 loss and Kras activation (8, 30, 31).”
BackgroundSelf-citationLu, J., Zhou, Z., Tang, M., Shen, H., Liu, Y., Wang, J., Jiang, Y., Chen, Y., & Wu, Z. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000638 · Cited by 6
Exploring the Role and Mechanism of pAMPKα‐Mediated Dysregulation of Brf1 and RNA Pol III Genes
Wu, T., Zhang, D., Lin, M., Yu, L., Dai, T., Li, S., Yu, F.-H., Lü, L., Zheng, L., & Zhong, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5554932 · Cited by 6
“AMPK is a primary component of the LKB1 downstream pathway, while mutations of LKB1 are found in over 20% of patients with NSCLC and frequently associated with activating K-RAS mutations [26 – 28].”
Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer
Ata, R., & Antonescu, C. N. (2021) · doi:10.32920/14639496.v1 · Cited by 6
Ibrahim, R., Lemoine, A., Bertoglio, J. H., & Raingeaud, J. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.014 · Cited by 5
Li, C., Yu, W. C., Deng, W., Fei, F., Wang, L., Qi, F., & Zheng, Z. (2021) · Open Medicine · doi:10.1515/med-2021-0375 · Cited by 5
“In addition, signaling molecules, especially liver kinase B1[16] and Kirsten rat sarcoma viral oncogene, are involved in the invasiveness and metastasis of LUAD [12].”
BackgroundA subset of VEGFR‐TKIs activates AMPK in LKB1 ‐mutant lung cancer
Yang, L., Zhang, Q., Xiong, Y., Dang, Z., Xiao, H., Chen, Q., Dai, X., Zhang, L., Zhu, J., Wang, D., et al. (2022) · Cancer Science · doi:10.1111/cas.15677 · Cited by 6
KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Izzo, L., Reyes, T., Meesala, S., Ireland, A. S., Earnest-Noble, L. B., Yang, S. S., Sunil, H. S., Cheng, X. C., Tserentsoodol, N., Hawgood, S. B., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-0531 · Cited by 6
“Given that mucinous histopathology precedes squamous differentiation in vivo (13, 20, 26, 35, 36, 76), we did not expect to observe mucinous-like cells in organoids, and consistently, mucinous markers were extremely rare and low (Supplementary Fig.”
Clinical trials unite mice and humans
Johnson, L. (2012) · Nature · doi:10.1038/483546a · Cited by 5
Oncogenesis, Inflammatory and Parasitic Tropical Diseases of the Lung
Kayembe, J.-M. (2013) · InTech eBooks · doi:10.5772/56085 · Cited by 5
STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications
Azin, M., & Demehri, S. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.003 · Cited by 5
“Inactivation of STK11 compared with that of other tumor suppressors, in cooperation with KRAS mutation, results in more frequent metastasis in lung adenocarcinoma (Ji et al., 2007).”
BackgroundKamarehei, F., Saidijam, M., & Taherkhani, A. (2023) · Genomics & Informatics · doi:10.5808/gi.22072 · Cited by 5
“Several studies have linked tumorigenesis, tumor-relevant defects, and the deregulation of mammalian target of rapamycin signaling proteins localized at cilia [109,110].”
BackgroundLopus, M., Paul, D., & Rajasekaran, R. (2016) · Cancer Informatics · doi:10.4137/cin.s38044 · Cited by 5
SOX2 in the Development and Maintenance of the Trachea, Lung, and Esophagus
Wong, N. C., Armin, P. M., Jiang, M., Ku, W.-Y., Jacobs, I., & Que, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800352-7.00017-7 · Cited by 6
Novel Genetic Algorithm for Early Prediction and Detection of Lung Cancer
Odeh, A., Atoum, I. A., & Bustanji, A. (2017) · Journal of Cancer Treatment and Research · doi:10.11648/j.jctr.20170502.13 · Cited by 7
“Process Time / second Michigan [11] 5.85307 Harvard [12] 33.90013 Harvard2 [12] 24.41596 Ontario [13] 40.81986 Proposed algorithm /Ontario 22.23 Moreover the selection process is used to create a two sets of high probability and the lowest one it’s just consume 0.91 second as shown in Figure 4.”
MethodInfluentialThe non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions
Horton, B. L., & Spranger, S. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170073 · Cited by 5
Whitsett, T. G., Mittal, S. K., Eschbacher, J. M., Carson, V. M., Smith, M. A., Bremner, R. M., & Inge, L. J. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.11.067 · Cited by 5
“In non–small cell lung carcinoma animal models, the deletion of Lkb1 in the context of mutant Kras was shown to be sufficient to induce distant metastases and shorter survival time.(27) Thus, the loss of LKB1 in EAC may promote more aggressive tumor types; however,”
BackgroundYao, S., Han, X., Tong, X., Li, F., Qin, Z., Huang, H., & Ji, H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/314393 · Cited by 6
“Interestingly, the mixed pathologies including both lung ADC and SCC in single lesions, clinically termed as adeno-squamous carcinoma (Ad-SCC), is detected in approximately 1-10% of lung cancer [1].”
BackgroundInfluentialSelf-citationTong, X., Zhang, N., Xue, Y., & Ji, H. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae013 · Cited by 5
“The Kras LSL-G12D/ + /Lkb1 flox/ flox (K D L) model is a well-established AST model reca-pitulating clinical phenotypic transition (Ji et al., 2007 ; Han et al., 2014 ; Li et al., 2015 ).”
Self-citationMethionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy ResponsePreprint
Naughton, K. J., Song, X., Childress, A. R., Skaggs, E. M., Byrd, A. L., Gosser, C. M., Esoe, D.-P. I., DuCote, T. J., Plaugher, D. R., Lukyanchuk, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.25.599795 · Cited by 6
“…using a genetically engineered mouse model (GEMM) of non-small cell lung cancer containing a single KrasG12D allele [43] with loxP sites flanking a STOP codon and both alleles of Lkb1 flanked by loxP sites [44] (LSL: KrasG12D ; Lkb1 flox/flox) leading the conditional Kras mut / Lkb1 mut mice [18].”
BackgroundMethodFan, Y., Li, M., Li, M., Zhu, S., Li, Y., Qin, X., Chang, J., Li, Y., Wu, L., Li, K., et al. (2026) · Materials Today · doi:10.1016/j.mattod.2026.01.001 · Cited by 4
Datta, C., Das, P., Dutta, S., Prasad, T., Banerjee, A., Gehlot, S., Ghosal, A., Dhabal, S., Biswas, P., De, D., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122857 · Cited by 4
Deng, H., Wang, Z., Zhu, C., & Chen, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1370393 · Cited by 5
Immune profiling of premalignant lesions in patients with Peutz‐Jeghers syndrome
Liu, Z., Wu, B., Shi, X., Zhou, J., Huang, H., Li, Z., & Yang, M. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12650 · Cited by 4
The Impact of Aging on Cancer Progression and Treatment
He, S., & Sharpless, N. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_3 · Cited by 5
Self-citation[Retracted] ROS Signaling‐Mediated Novel Biological Targets: Brf1 and RNA Pol III Genes
Zheng, L., Lin, Y., & Zhong, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5888432 · Cited by 4
RetractedMcGrail, K., González‐Sánchez, E., Granado‐Martínez, P., Orsenigo, R., Ding, Y., Fábrega, B. F., Hernández‐Losa, J., Ortega, I., Martín‐Caballero, J., Muñoz‐Couselo, E., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13715 · Cited by 6
“LKB1 has been found to be mutated in several tumor types, such as lung cancer [16,17], cervical cancer [18], pancreatic cancer [19,20], breast cancer [21], and malignant melanoma [22,23].”
Sengottuvel, N., Whately, K. M., Modliszewski, J. L., Sellers, R. S., Green, W. D., Gong, W., Woods, A. T., Livingston, E. W., Fagan‐Solis, K. D., Cannon, G., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.171364 · Cited by 4
Glycolytic Pathway as a Target for Tumor Inhibition
Lu, W., & Huang, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_5 · Cited by 4
Zheng, G., Song, K., & Zhao, Y. (2019) · Neoplasma · doi:10.4149/neo_2018_180820n630 · Cited by 4
“[17] JI H, RAMSEY MR, HAYES DN, FAN C, MCNAMARA K et al.”
BackgroundLoss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice
Branca, J. A., Low, B. E., Saxl, R. L., Sargent, J. K., Doty, R. A., Wiles, M. V., Dumont, B. L., & Hasham, M. G. (2020) · Genes & Cancer · doi:10.18632/genesandcancer.198 · Cited by 4
“To shorten tumor latency time, Trp53 is often deleted [63, 64].”
Hotspots and trends in liver kinase B1 research: A bibliometric analysis
Song, Y., Zhao, F., Ma, W., & Li, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259240 · Cited by 4
Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
Zhou, W., Yan, L.-D., Yu, Z.-Q., Li, N., Yang, Y., Wang, M., Chen, Y., Mao, M.-X., Peng, X., & Cai, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13301 · Cited by 5
“Although STK11 is inactivated by a large spectrum of truncating mutations and behaves like a tumor‐suppressor gene in different tumor models through mTOR repression (77,82,83), recent studies have shown that STK11 may also acquire oncogenic properties.”
BackgroundPalbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase
Fujii, T., Kamishikiryo, J., & Morita, T. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00365-0 · Cited by 4
“AMPK may suppress the proliferation of cancer cells by inducing autophagy [31, 32]; however, it has been reported that AMPK acts both to suppress and promote cancer cell proliferation [33].”
BackgroundGlucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
Huffman, K. E., Li, L. S., Carstens, R. M., Park, H., Girard, L., Avila, K., Wei, S., Kollipara, R. K., Timmons, B. C., Sudderth, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1025443 · Cited by 4
Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma
Yousefi, M., Andrejka, L., Szamecz, M., Winslow, M. M., Petrov, D. A., & Boross, G. Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303224120 · Cited by 4
“We chose loss - of - function mutations in Keap1 and Lkb1 ( Stk11 ) which are known tumor suppressor genes that are frequently mutated in human lung cancer and have been shown to suppress growth in models of oncogenic KRAS - driven lung adenocarcinoma (17, 18, 21–23).”
BackgroundLung cancer: microRNA and target database.
Challa, K., & Deepika, P. (2012) · 中国肺癌杂志 · doi:10.3779/j.issn.1009-3419.2012.07.07 · Cited by 4
RetractedQin, Z. S., Xie, R., Zhang, W., Wan, M., Zhang, L., Wang, H., Li, N., Qin, Q., & Yao, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.12.06 · Cited by 4
“reported that LKB1 alteration was detected in 19% lung squamous cell carcinoma and 34% lung adenocarcinoma (23).”
BackgroundJAK1/2 Inhibition Delays Cachexia and Improves Survival through Increased Food IntakePreprint
Dantas, E., Murthy, A., Kim, J., Ahmed, T., Ahmed, M., Perrier, T., Ramsamooj, S., Nathoo, I., Debarba, L. K., Queiroz, A. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683287 · Cited by 4
Ihle, N. T. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 6
Pentimalli, F. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2220 · Cited by 3
Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Tomanelli, M., Guffanti, F., Vargiu, G., Micotti, E., Rigamonti, M., Tumiatti, F., Caiola, E., Marabese, M., & Broggini, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504938 · Cited by 4
Zhang, Z., Li, J., Willis, D., Shi, S., Tu, H., & Costa, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094207 · Cited by 3
“Neural precursor cell expressed developmentally downregulated 9 (NEDD9), also known as HEF1, is a multi-domain scaffolding protein that organizes signaling complexes involved in key processes of tumorigenesis and metastasis [12,13].”
Skouradaki, E., Zaravinos, A., Παναγοπούλου, Μ., Chatzaki, Ε., Dovrolis, N., & Baritaki, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157145 · Cited by 3
“Additionally, expression profiling in human lung cancer cell lines and mouse lung tumors revealed several metastasis-promoting genes, including NEDD9 , VEGFC , and CD24 , as targets of LKB1 repression [63].”
Wang, L., Wu, T., & Tsai, F. (2025) · Cell Biology International · doi:10.1002/cbin.70108 · Cited by 3
“STK11 (LKB1) inactivation promotes KRAS ‐ driven tumor development, resulting in increased pathological heterogeneity and metastatic potential (Ji et al. 2007).”
Chen, N., Fang, M., Zhong, L., Li, X., Zhou, Y., Zhan, J., Wang, M., Fang, Z., Wang, H., Tang, S., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-025-01657-7 · Cited by 9
“Previous studies have identi fi ed genetic drivers such as loss of tumor suppressor LKB1, which destabilize adenocarcinoma identity and facilitate this switch [17].”
Self-citationZhang, Z.-D., Lin, Y.-L., Zhang, H.-Y., Zuo, C., Zhong-Lin, Z. H. U., Wang, X.-Y., Hao-Yu, D. U. A. N., Zhang, J., Lin, D., & Zhong, B. (2026) · Developmental Cell · doi:10.1016/j.devcel.2025.12.007 · Cited by 4
Guo, W., Lu, T. L., Song, Y., Li, A., Feng, X., Han, D., Cao, Y., Sun, D., Gong, X., Li, C., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70039 · Cited by 6
“40 In clinic, KRAS / STK11 comutation patients showed a poorer prognosis and primary resistance to PD-1 axis inhibitors.”
BackgroundMével‐Aliset, M., Radu, A. G., Allard, J., Blanchet, S., Montellier, E., Hainaut, P. L., Rossignol, R., Torch, S., Orsi, G. A., & Thibert, C. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151571 · Cited by 3
Analysis of miRNA expression profile in lung tissues of an intermittent hypoxia rat model
Liu, Z., Ai, L., Li, R., Yang, Y., Chen, K., He, C., & Li, Y. (2021) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2021.103741 · Cited by 4
Dual data and motif clustering improves the modeling and interpretation of phosphoproteomic data
Creixell, M., & Meyer, A. S. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100167 · Cited by 5
“Inactivating somatic mutations in the tumor suppressor STK11 leads to increased tumorigenesis and metastasis (Ji et al., 2007).”
BackgroundAMPK-like proteins and their function in female reproduction and gynecologic cancer
Baumgartner, C., Yadav, A. K., & Chefetz, I. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.016 · Cited by 3
Using 3-Dimensional Cultures to Propagate Genetically Modified Lung Organoids
Chen, F., Naughton, K. J., Lee, J., & Brainson, C. F. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3854-5_2 · Cited by 3
Genetically Engineered Mouse Models in Preclinical Anti-Cancer Drug Development
Sergio, Y., & Melinda, G. (2011) · InTech eBooks · doi:10.5772/30666 · Cited by 9
Zaba, O., Holbe, D., Aretz, S., & Grohé, C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.019 · Cited by 3
“It was recently shown that the loss of the LKB1 tumour uppressor gene in Kras-driven lung tumours results in increased etastasis to lymph node and distant sites in mice [7].”
BackgroundNew Scope of Targeted Therapies in Lung Carcinoma
Sonkar, A. B., Kumar, P., Gautam, A. K., Maity, B., & Saha, S. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210805104714 · Cited by 3
Li, D., Zhou, Y., Liu, Y., Lin, Y., Yu, M., Lu, X., Huang, B., Sun, Z., Jian, Z., & Hou, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s154168 · Cited by 3
“Previous research revealed that LKB1 acts as a critical barrier to pulmonary tumorigenesis through inhibiting cell differentiation and epithelial–mesenchymal transition.(31) LKB1 has also been implicated in regulating the differentiation of a number of other cell types, such as colonic epithelial cancer cell, pancreat…”
Self-citationBissler, J. J. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7784-0_3 · Cited by 5
Experimental Animal Models for Lung Cancer
Üstüner, C., & Entok, E. (2019) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2019.0006 · Cited by 4
“Bu sistemle oluşturulan bir diğer oldukça favori olan model ise Lkb1:LSLK-RasG12D’ dir ve insan metastazına oldukça benzer adenokarsinomlar ve skuamöz hücre karsinomları gelişir (52).”
Zhou, S., Li, Y., Qiao, L., Ge, Y., Huang, X., Gao, X., Ju, H., Wang, W. J., Zhang, J., Yan, J., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900294rr · Cited by 3
“As a tumor suppressor, LKB1 is inactive inawidevarietyof sporadic cancers,most of which show inactivation of AMPKs and a hyperactivation of mTORC1 signaling (5, 41, 42).”
BackgroundRen, Y., Chen, J., Mo, X., Yang, Q., Chen, P., Lu, G. X., Tan, H. W. S., Yi, J., Yu, Q., Kim, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622126 · Cited by 3
“Moreover, genomic analyses of NSCLC tumor samples have revealed that LKB1 mutations co-occur with KRAS mutations in about 10% of NSCLC patients (Ding et al., 2008; Ji et al., 2007; Makowski and Hayes, 2008).”
BackgroundInfluentialSustained Glucose Turnover Flux Distinguishes Cancer Cachexia from Nutrient LimitationPreprint
Kwon, Y., Liang, Y., Gomez-Jenkins, M., Ahmed, M., Jiang, G., Hsiang, J., Lewis, D. Y., Janowitz, T., Goncalves, M. D., White, E. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.15.654370 · Cited by 3
Somatic Genome Alterations in Human Lung Cancers
Imielinski, M. B., Hammerman, P. S., Thomas, R. K., & Meyerson, M. M. (2014) · Wiley eBooks · doi:10.1002/9781118468791.ch4 · Cited by 2
Self-citationKerr, K. M. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_13 · Cited by 2
Uso de la metformina en cáncer ginecológico
Troconis, N. (2021) · doi:10.47307/gmc.2021.129.1.12 · Cited by 3
Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer
Zhu, L., Jia, X., Xu, L., Chen, L., Fu, X., Yan, H., Ai, B., & Peng, S. (2025) · iScience · doi:10.1016/j.isci.2025.114429 · Cited by 4
“58 The synergistic oncogenic effect between STK11 inactivation and KRAS activation has been revealed to arise from multifaceted factors involving epigenetic re-programming, metabolic alterations, shifts in signaling pathway dependencies, and the shaping of an immunologically ‘‘cold’’ tumor…”
Self-citationConcurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer
Yue, M., Qin, Z., Tang, S., Cai, X., Zhao, Y., Yang, C., Chen, L., Chen, L., & Ji, H. (2025) · Nature Communications · doi:10.1038/s41467-025-67345-9 · Cited by 4
Self-citationMen, Y. N., Chen, J. N., Cai, H., & Yang, C. N. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl45346 · Cited by 2
The roles of IKKα in normal physiology and cancer
Besta, S., Samuels, M. E., Roupakia, E., Kanellis, D. C., Marcu, K. B., & Kolettas, E. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02882-4 · Cited by 2
Tang, Q., Lian, C., Han, X., Zhang, X., Wang, Z., Wang, B., Zhu, T., Lin, X., Wang, X., Xu, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.75839 · Cited by 3
Self-citationMolecular Biology and Genetics of Lung Cancer
Milanović, D. (2011) · Medical radiology · doi:10.1007/174_2011_310 · Cited by 2
Brainson, C. F., & Kim, C. F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00006-1 · Cited by 2
Prognostic implication of proteomic profiles in head and neck squamous cell carcinoma
Wu, D., Gong, P., Zeng, Q., Zhang, W., Xie, F., & Zhou, X. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.022 · Cited by 3
Cancer Metastasis - Molecular Mechanism and Clinical Therapy
Tutar, Y., & Tutar, L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100926 · Cited by 2
LKB1 and CRMP1 cooperatively promote the repair of the sciatic nerve injury
Liu, Y., & Xu, Y. (2023) · Developmental Neurobiology · doi:10.1002/dneu.22932 · Cited by 2
“The serine/threonine kinase 11 (LKB1 or STK11) gene is the pathogenic gene of Peutz–Jeghers syndrome (PJS), and its encoded product is a serine/threonine protein kinase (Cic-carese et al., 2019; Ji et al., 2007; Zhang et al., 2021).”
BackgroundHwang, J. Y., Lee, N. S., Lee, C., Lam, K. H., Kim, H. H., Zhou, Q., Chow, R. H.-P., & Shung, K. K. (2012) · IEEE International Ultrasonics Symposium · doi:10.1109/ultsym.2012.0148 · Cited by 2
“Currently, the only way to determine tumor cell invasion potentials is use of matrigel barrier-based methods [4-6].”
Winning the Cancer Fight: A Look at the Future
Eyre, H. J. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.07.003 · Cited by 2
Energizing the Search to Target LKB1-Mutant Tumors
Marcus, A. I., & Khuri, F. R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0296 · Cited by 2
Par Proteins in Tumor Formation and Progression
Mescher, M., & Iden, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-14466-5_6 · Cited by 4
Activity-Based Proteomics: Methods and Protocols
Tao, Z. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4502-4 · Cited by 3
Molecular Pathology of Lung Cancer
Corvalán, A. H., & Wistuba, I. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_1 · Cited by 2
Autophagy: Noble target mechanisms in natural medicines as anticancer agents
Kang, S. (2010) · Journal of Plant Biotechnology · doi:10.5010/jpb.2010.37.1.057 · Cited by 2
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
Fennell, D. A., & Swanton, C. (2012) · The EPMA Journal · doi:10.1186/1878-5085-3-6 · Cited by 3
“Sequencing efforts have identified mutations of KRAS, B-RAF, Her2/erbb2, PIKC3A, LKB1 and MET amplification [103-105].”
BackgroundAnimal models and in vivo investigations for drug repurposing in lung cancer
Chang, H.-W. K., & Chang, V. H. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00010-5 · Cited by 2
The role of liver kinase B1 in tumor progression through regulation of lipid metabolism
Geng, J., Zhang, Y., Meng, Q., Yan, H., & Wang, Y. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02863-2 · Cited by 3
Popper, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-55743-0_17 · Cited by 2
Politi, K. A., Cruz, C. S. D., & Homer, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05310-7 · Cited by 2
Shu, C., Jin, R., Niu, Q., Cicka, D., Doyle, S. P., Wahafu, A., Fan, D., Zheng, X., Du, Y., Ivanov, A. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.17.460294 · Cited by 2
Samson, S. C., Rojas, A., Zitnay, R. G., Carney, K. R., Hettinga, W., Schaelling, M. C., Sicard, D., Zhang, W., Gilbert‐Ross, M., Dy, G. K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.17.613509 · Cited by 2
Yue, Y., Hua, Y., Zhang, J., Guo, Y. M., Zhao, D., Huo, W., Xiong, Y., Chen, F., Lin, Y., Xiong, X., et al. (2022) · Journal of Applied Animal Research · doi:10.1080/09712119.2022.2042001 · Cited by 1
“2017) and cancer differentiation and metastasis (Ji et al. 2007).”
BackgroundAlshammary, A. F., Al-Toub, M., Albukhari, T. A., & Filimban, W. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124606123010009 · Cited by 1
The role of LKB1 in prostate cancer: implications for tumor progression and therapy
Liang, Y., Cao, H., Tang, Z., Li, S., Yang, G., Dong, S., Du, H., & Wang, J. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1629844 · Cited by 2
“For example, genetic studies in mouse models have shown that the absence of LKB1 alone is insufficient to drive malignant transformation in many tissues, but dramatically enhances oncogenesiswhencombinedwithothermutationsorenvironmental challenges (Ji et al., 2007).”
Busk, M., Thomsen, M. K., Overgaard, J., Berthelsen, M. F., Hager, H., Bussink, J., Hansen, K. V., Jakobsen, S., Lilja‐Fischer, J. K., Boedtkjer, E., et al. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.44002 · Cited by 1
“In the present study, we inactivated the tumor suppressor LKB1, which is mutated in 35% of lung adenocarcinomas [30].”
Obesity Worsens Arsenic Trioxide-Induced Myocardial Toxicity and Its Protection by Metallothionein
Ge, T., qian, L., Li, A., Guo, Q., Liu, Q., & Cui, J. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10085-5 · Cited by 1
“Histological staining was performed as previously described [17 ].”
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.